Literature DB >> 2170808

Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer.

C Toniatti1, R Arcone, B Majello, U Ganter, G Arpaia, G Ciliberto.   

Abstract

Human C-reactive protein (CRP) is the major acute phase reactant during inflammation. Regulation of CRP gene expression has been studied in two experimental systems: transgenic mice and human hepatoma cells. In the first system the human CRP gene flanked by approximately 10(4) bases of 5' and 3' sequences is expressed in a liver-specific and inducible manner. The chromatin configuration of the CRP transgene is characterized by the presence of constitutive and inducible liver-specific DNase I-hypersensitive sites. Inducible sites map precisely at the level of the CRP promoter region. In hepatoma cells we analysed the expression of the bacterial chloramphenicol acetyltransferase (CAT) gene driven by various segments of the CRP promoter. This latter approach has led to the identification of promoter elements responsive to interleukin-6 and of hepatocyte-specific nuclear proteins that interact with them.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170808

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  20 in total

1.  Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo.

Authors:  B Weinhold; A Bader; V Poli; U Rüther
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

3.  C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Authors:  Brian I Carr; Hikmet Akkiz; Vito Guerra; Oguz Üsküdar; Sedef Kuran; Ümit Karaoğullarından; Salih Tokmak; Tuğsan Ballı; Abdulalh Ülkü; Tolga Akçam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal Yalçın; Engin Altntaş; Ayşegül Özakyol; Mehmet Yücesoy; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necat Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

4.  Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter.

Authors:  Bhavya Voleti; David J Hammond; Avinash Thirumalai; Alok Agrawal
Journal:  Mol Immunol       Date:  2012-06-29       Impact factor: 4.407

5.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat alpha 2 macroglobulin gene.

Authors:  G M Hocke; D Barry; G H Fey
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

7.  Cloning and tissue-specific expression of the gene for mouse C-reactive protein.

Authors:  N O Ku; R F Mortensen
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

8.  Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies.

Authors:  Chung-Pin Li; Tze-Sing Huang; Yee Chao; Full-Young Chang; Jacquline Whang-Peng; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

9.  Value of measurement of C-reactive protein in febrile patients with hematological malignancies.

Authors:  E Rintala; K Irjala; J Nikoskelainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

10.  Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.

Authors:  C Toniatti; A Demartis; P Monaci; A Nicosia; G Ciliberto
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.